Labcorp Holdings (LH) stock is drawing attention after recent trading, with shares last closing at $266.34. For investors, the current setup puts fresh focus on its valuation and underlying business mix.

The latest 1 day share price return of 0.44% comes on top of a 7 day share price return of 4.11% and a year to date share price return of 5.83%. Total shareholder returns over 3 years and 5 years of 33.67% and 17.36% respectively suggest Labcorp Holdings has delivered steadier progress over longer periods than over the past year alone.

If you are assessing Labcorp Holdings and want to broaden your watchlist, this is a good moment to look at other healthcare testing and treatment plays through 39 healthcare AI stocks

With Labcorp Holdings trading at $266.34 alongside solid multi year total returns and an indicated intrinsic discount, the key question is whether the stock still offers value or if the market is already pricing in future growth.

Most Popular Narrative: 14.1% Undervalued

With Labcorp Holdings last closing at $266.34 against a widely followed fair value estimate of about $310, the current narrative leans toward underpricing its cash generation and earnings potential.

The introduction of new tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

Want to understand why this valuation leans higher than today’s price? The core of the narrative rests on steadier revenue gains, improving margins, and a future earnings profile that assumes a different mix of testing volume and profitability than the current market seems to reflect.

Result: Fair Value of $310.12 (UNDERVALUED)

However, this Labcorp Holdings narrative could be challenged if tariffs and regulatory changes raise costs, or if tougher competition squeezes pricing and margins in diagnostics.

Another View on Labcorp Holdings Valuation

The earlier narrative leans on cash flows and long term earnings to suggest Labcorp Holdings is trading below fair value. On a simpler P/E basis though, the stock looks only slightly expensive versus its own fair ratio of 23.1x at 23.2x today, yet cheaper than peers at 37.1x and the broader US Healthcare industry at 23.6x. Is that a margin of safety, or a sign the market is already closer to fair on earnings?

For a closer look at how these earnings multiples stack up against the fair ratio trend, and what that might mean for upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seen enough to sense where sentiment on Labcorp Holdings might be heading? Act quickly by checking the detailed data, weighing both potential rewards and flagged risks, then judge the balance for yourself with 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Labcorp Holdings?

If Labcorp Holdings has sharpened your focus, do not stop here. Fresh ideas often come from comparing it with stocks that offer different return and risk profiles.

• Spot potential bargains early by checking companies that appear priced below their fundamentals through the 43 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier at night by reviewing stocks in the 67 resilient stocks with low risk scores.
• Hunt for potential future standouts that are not widely followed yet, starting with the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.